Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Merck Research Laboratories Direct Human Health R&D by Quarter
Merck Research Laboratories (MRL) Direct Human Health R&D ($B)
Merck Merck Research Laboratories Direct Human Health R&D: $2.80B in Q2 2026.
Latest, Q2 2026
2.80
Period ended Jun 30, 2026
Change on a year earlier
–
History
1 quarters
Since Q2 2026
Sources
1
Form 10-Q (mrk-20260630.htm, filed 2026-08-07)
Where the Q2 2026 figure comes from
“R&D expenses consist of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $2.8 billion and $5.3 billion in the second quarter and first six months of 2026”
Source: Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Reported in Form 10-K MD&A Research and Development.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Merck Research Laboratories (MRL) Direct Human Health R&D ($B) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2.80 | – | Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗ |
Cite this data
StockData. (2026). Merck Merck Research Laboratories Direct Human Health R&D, quarterly Q2 2026–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rd-mrl-direct-b
See every metric in the Merck KPI table. Data updated Oct 26, 2026.